FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending June 06, 2008
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
The Company was notified on the 5th June 2008 that on 2nd June 2008 Mr S A Hussain , a Person Discharging Managerial Responsibility, received a deferred investment award equivalent to 35,778.18 Ordinary shares at £11.18 per Ordinary share.
Fifty per cent of the award will vest on 2nd June 2012, a further twenty five per cent will vest on 2nd June 2013, with the remainder vesting on 2nd June 2014.
This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
S M Bicknell
Company Secretary
6 June 2008
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorised.
GlaxoSmithKline plc
(Registrant)
Date: June 06, 2008
By: VICTORIA WHYTE
------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc